Due Diligence

If you want to evaluate potential business opportunities or if you want to license a new product you will need specific advice. Due diligence reports and feasibility studies can protect you from some of the uncertainties that often arise during the course of a development project.

Making the right decision is always essential to commercial success. If you are wondering whether or not to buy a development product or whether to proceed with a project, whether it is feasible as envisaged and whether the project could be financially viable, we can help you make the right decision. At HORN Pharmaceutical Consulting we have the necessary experience to help you to explore the status of a development project. We provide you with valuable due diligence reports about the new products you are interested in. We also support you throughout the due diligence process with specific pharmaceutical and regulatory advice.

Our due diligence services include a thorough investigation of adequate solutions to a problem and a recommendation on the best alternatives. We will evaluate the project status, define regulatory hurdles to overcome and will estimate the likeliness of success for a development program from clinical trials to submission.

With a network of partners, HORN Pharmaceutical Consulting provides multidisciplinary and comprehensive professional services in the area of product licensing or co-development and feasibility studies. We guarantee strict confidentiality and adherence to professional standards of excellence. Our specialists will work together with you to define optimal solutions for your product and to optimize your business strategies.


Our specifically tailored services include:
  • Review of product development status
  • Evaluation of product development strategy
  • Analysis of regulatory challenges and marketing opportunities
  • Review of competitors
  • Feasibility studies
  • Provision of due diligence reports
  • Support in due diligence discussions with potential cooperation partners


Phone +49 (0) 7251/305 529
Fax +49 (0) 7251/305 528


Get all events


  • 19.12.2022
    EU Update regarding Deadlines of Nitrosamine Impurities
  • 01.09.2022
    EU-GMP Annex 1 finally published
  • 26.08.2022
    New Deadlines and Chances for Nitrosamines
Get all news